STEREOCHEMICAL COURSE OF THE ALKALINE DECARBOALKOXYLATIVE CYCLIZATION OF C(4)-, C(5)- AND C(4),C(5)-SUBSTITUTED 1-[2-(3-INDOLYL)ETHYL]-3-METHOXYCARBONYL-1,4,5,6-TETRAHYDROPYRIDINES TO C(2)-, C(3)- AND C(2),C(3)-SUBSTITUTED INDOLO[2,3-a]QUINOLIZIDINES

MAURI LOUNASMAA\*, REIJA JOKELA, PIRJO MÄKIMATTILA and BIRGIT TIRKKONEN

Laboratory for Organic and Bioorganic Chemistry,
Technical University of Helsinki, SF-02150 Espoo, Finland

(Received in UK 18 December 1989)

Alkaline decarboalkoxylative cyclization of C(4)-Abstract 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-1,4,5,6monosubstituted tetrahydropyridines la and ld leads mainly to C(2)-monosubstituted indolo[2,3-a]quinolizidines 2a and 2d possessing the C(12b)H-C(2)H cis relationship [corresponding to the C(3)H-C(15)H cis relationship when the biogenetic numbering of indole alkaloids is used]. The C(5)-monosubstituted 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-1,4,5,6-tetrahydropyridine le yields almost exclusively C(3)monosubstituted indolo[2,3-a]quinolizidine 3e [C(12b)H-C(3)H trans relationship]. In the case of the C(4),C(5)-disubstituted analogues 1g, the C(12b)H-C(2)H relationship is strongly influenced by the C(4)H-C(5)H relationship (cis or trans) of the original 1,4,5,6tetrahydropyridine. Thus  $1-[2-\overline{(3-indoly1)}ethy1]-3-methoxycarbonyl-4$ methyl-5-ethyl-1,4,5,6-tetrahydropyridine 1f [C(4)H-C(5)Hleads to 2-methyl-3-ethylindolo[2,3-a]quinolizidines relationshipl 3f and 2f [C(12b)H-C(2)H trans and cis relationships, respectively] īn 98:2 ratio, whereas 1-[2-(3-indoly1)ethy1]-3methoxycarbonyl-4-methyl-5-ethyl-1,4,5,6-tetrahydropyridine  $\underline{1g}$  [C(4) trans relationship] yields exclusively 2-methyl-3ethylindolo[2,3-a]quinolizidine 2g [C(12b)H-C(2)H cis relationship].

More than a decade ago we showed that the alkaline decarboalkoxylative cyclization (alkaline hydrolysis followed by decarboxylation and cyclization) of 1-[2-(3-indoly1)ethy1]-3-methoxycarbony1-4-methy1-1,4,5,6-tetrahydropyridine <u>1a</u> leads to 2-methylindolo[2,3-a]quinolizidine <u>2a</u> possessing the C(12b)H-C(2)H <u>cis</u> relationship. In this connection we expressed doubts concerning the preparation of <u>dl</u>-18,19-dihydroantirhine <u>3b</u>

[C(3)H-C(15)H  $\underline{\text{trans}}$  relationship when the biogenetic numbering<sup>6</sup> is used, corresponding to the C(12b)H-C(2)H  $\underline{\text{trans}}$  relationship in IUPAC numbering] by alkaline decarboalkoxylative cyclization of 1,4,5,6-tetrahydropyridine 1b, as claimed by Wenkert et al.<sup>7</sup> (Scheme 1).

### Scheme 1

In connection with our recent stereoselective syntheses of  $\underline{d1}$ -18,19-dihydroantirhine  $\underline{3b}$  and  $\underline{d1}$ -3-epi-18,19-dihydroantirhine  $\underline{2b}$ , we repeated the alkaline decarboalkoxylative cyclization of 1,4,5,6-tetrahydropyridine  $\underline{1b}$ .8 As expected, we found that the product formed was not  $\underline{d1}$ -18,19-dihydroantirhine  $\underline{3b}$  as claimed by Wenkert  $\underline{et}$  al.7 but  $\underline{d1}$ -3-epi-18,19-dihydroantirhine  $\underline{2b}$ . We further confirmed our findings by showing that the alkaline decarboalkoxylative cyclization of 1,4,5,6-tetrahydropyridine  $\underline{1c}$  leads to  $\underline{d1}$ -3-epi-18-nor-18,19-dihydroantirhine  $\underline{2c}$  (Scheme 1).9

In view of the criticism of our conclusions regarding the general stereochemical course of the alkaline decarboalkoxylative cyclization of C(4)-substituted 1-[2-(3-indoly1)ethy1]-3-methoxycarbony1-1,4,5,6-tetra-hydropyridines to C(2)-substituted indolo[2,3-a]quinolizidines and the claim of ubiquitous C(12b)H-C(2)H trans product formation, presented by Wenkert et al. $^4$ ,5,7,10,11, we have now examined the reaction in more detail.

#### RESULTS AND DISCUSSION

Treatment of nicotinic acid methyl esters  $4a^{12}$ ,  $4d^{12}$ ,  $4e^{13}$  and  $4f^4$  with tryptophyl bromide 4 yielded 1-[2-(3-indolyl)ethyl]-3-methoxycarbonyl

$$CO_2CH_3$$
 $CO_2CH_3$ 
 $CO_2CH_3$ 

pyridinium bromides  $\underline{5a}$ ,  $\underline{5d}$ ,  $\underline{5e}$  and  $\underline{5f}$ , respectively, which were transformed by catalytic hydrogenation (Pd, Et<sub>3</sub>N) to the corresponding 1,4,5,6-tetrahydropyridines  $\underline{1a}$ ,  $\underline{1d}$ ,  $\underline{1e}$  and  $\underline{1f}$  (Scheme 2).

$$\underline{\alpha}$$
,  $R_1 = CH_3$ ;  $R_2 = H$ 

$$d$$
,  $R_1 = CH_2 - CH_2 - CH_3$ ;  $R_2 = H$ 

$$e$$
,  $R_1 = H$ ;  $R_2 = CH_2 - CH_3$ 

$$f$$
,  $R_1 = CH_3$ ;  $R_2 = CH_2 - CH_3$ 

## Scheme 2

Sodium dithionite reduction  $^{12}$ ,  $^{15}$ - $^{19}$  of  $^{1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl pyridinium bromide <math>^{5f}$  using NaHCO<sub>3</sub> buffer afforded the corresponding 1,4-dihydropyridine  $^{6f}$ . Catalytic hydrogenation (Pd, Et<sub>3</sub>N) of the 1,4-dihydropyridine  $^{6f}$  led to a 70:30 mixture of 1,4,5,6-tetrahydro-

pyridines 1f (vide supra) and 1g (Scheme 3).

Scheme 3

Reinvestigation of the alkaline decarboalkoxylative cyclization of  $1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-4-methyl-1,4,5,6-tetrahydropyridine <math>\underline{1a}^1$  to 2-methylindolo[2,3- $\underline{a}$ ]quinolizidine  $\underline{2a}$  revealed the simultaneous formation in small amount (3%) of the isomeric 2-methylindolo[2,3- $\underline{a}$ ]quinolizidine  $\underline{3a}$  (Scheme 4).

## Scheme 4

Alkaline decarboalkoxylative cyclization of 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-4-propyl-1,4,5,6-tetrahydropyridine 1d afforded 2-propylindolo[2,3-a]quinolizidine 2d as the main product, together with 6% of the isomeric 2-propylindolo[2,3-a]quinolizidine 3d (Scheme 4).

Alkaline decarboalkoxylative cyclization of C(5)-monosubstituted 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-1,4,5,6-tetrahydropyridine  $\underline{1e}$  led to 3-ethylindolo[2,3- $\underline{a}$ ]quinolizidines  $\underline{3e}$  and  $\underline{2e}$  in about 98:2 ratio (Scheme 5).

### Scheme 5

In the case of C(4),C(5)-disubstituted  $1-[2-(3-indoly1)ethy1]-3-methoxy-carbonyl-1,4,5,6-tetrahydropyridines <math>\underline{1f}$  and  $\underline{1g}$ , the final C(12b)H-C(2)H relationship is strongly influenced by the C(4)H-C(5)H relationship ( $\underline{cis}$  or  $\underline{trans}$ ) of the original 1,4,5,6-tetrahydropyridine. Thus  $1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-4-methyl-5-ethyl-1,4,5,6-tetrahydropyridine <math>\underline{1f}$  led to 2-methyl-3-ethylindolo[2,3- $\underline{a}$ ]quinolizidines  $\underline{3f}$  and  $\underline{2f}$  in about 98:2 ratio (Scheme 6), whereas 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-

## Scheme 6

4-methyl-5-ethyl-1,4,5,6-tetrahydropyridine  $\underline{1g}$  yielded exclusively 2-methyl-3-ethylindolo[2,3-a]quinolizidine  $2g^{20}$  (Scheme 7).

Scheme 7

For purposes of comparison, compounds 2a, 2d, 2e, 2f, 3a, 3d, 3e and 3f were also synthesized (vide infra) by an alternative route, using our recently developed method for stereoregulation in the preparation of C(1)-, C(2)-, C(3)- and C(2),C(3)-substituted indolo[2,3-a]quinolizidines.8,21-23

Pyridinium salts 7a, 7d, 7e and 7f (prepared from tryptophyl bromide 14 and pyridine derivatives  $8a^{24}$ ,  $8d^{25}$ ,  $8e^{26}$  and  $8f^{27}$ , respectively) were

$$\frac{1}{N}$$

$$\frac{8a}{N}$$

$$\frac{8a}{N}$$

$$\frac{8e}{N}$$

$$\frac{8f}{N}$$

transformed by NaBH<sub>4</sub> reduction and cyanide trapping to  $\alpha$ -aminonitriles  $\underline{9a}$ ,  $\underline{9d}$ ,  $\underline{9e}$  and  $\underline{9f}$ , which by acid treatment yielded indolo[2,3- $\underline{a}$ ]quinolizidines  $\underline{10a}$ ,  $\underline{10d}$ ,  $\underline{10e}$  and  $\underline{10f}$ , respectively. Parts of the compounds  $\underline{10a}$ ,  $\underline{10d}$ ,  $\underline{10d}$  and  $\underline{10f}$  were transformed with  $\underline{di-t}$ -butyl dicarbonate [(BOC)<sub>2</sub>O] to the corresponding BOC-protected indolo[2,3- $\underline{a}$ ]quinolizidines  $\underline{11a}$ ,  $\underline{11d}$ ,  $\underline{11e}$  and  $\underline{11f}$  (Scheme 8).

Scheme 8

Catalytic hydrogenation (PtO<sub>2</sub>) of compounds  $\underline{10a}$ ,  $\underline{10d}$ ,  $\underline{10e}$  and  $\underline{10f}$  afforded compounds  $\underline{2a}$ ,  $\underline{2d}$ ,  $\underline{2e^{28}}$  and  $\underline{2f}$ , whereas the same treatment of the BOC-protected compounds  $\underline{11a}$ ,  $\underline{11d}$ ,  $\underline{11e}$  and  $\underline{11f}$  led,  $\underline{via}$  compounds  $\underline{12a}$ ,  $\underline{12d}$ ,  $\underline{12e}$  and  $\underline{12f}$ ,  $\underline{29}$  to compounds  $\underline{3a}$ ,  $\underline{3d}$ ,  $\underline{3e}$  and  $\underline{3f}$ , respectively (Scheme 8).

The  $^{13}$ C NMR data of compounds 1d, 1e, 1f, 6f, 1g, 2d, 2f, 2g, 3d, 3f, 9d, 9f, 10d, 10f, 11d, 11f, 12d and 12f are given in Fig. 1. For those of compounds 1a and 2a, see Ref. 1 (compounds 1b and 5d), for those of compounds 3a, 9a, 10a, 11a and 12a, see Ref. 21 (compounds 7b, 2b, 3b, 5b and 6b), for those of compounds 9e, 10e, 11e and 12e, see Ref. 31 (compounds 2, 3, 5 and 9) and for those of compounds 2e and 3e, see Ref. 32 (compounds 3e and 4e).

Fig. 1

Fig. 1 (continued)

Comparison of the chemical shifts found for compounds 2d, 2f, 2g, 3d, 3f, 10d, 10f, 11d, 11f, 12d and 12f with those given earlier, 21, 31, 32 taking into account the conformational considerations relevant for indolo[2,3-a]quinolizidines, 21, 33 provides clear evidence for the stereostructures depicted in the formulae.

#### CONCLUSIONS

The alkaline decarboalkoxylative cyclization of C(4)-monosubstituted 1-[2-(3-indoly1)ethy1]-3-methoxycarbony1-1,4,5,6-tetrahydropyridines 1a and 1d leads preponderantly to indolo[2,3-a]quinolizidines 2a and 2d possessing the C(12b)H-C(2)H cis relationship. The C(5)- monosubstituted 1-[2-(3indoly1)ethy1]-3-methoxycarbony1-1,4,5,6-tetrahydropyridine 1e yields nearly exclusively indolo[2,3- $\underline{a}$ ]quinolizidine  $\underline{3e}$  possessing the C(12b)H-C(3)H trans relationship. The preponderance of the C(12b)H-C(3)H trans relationship seems to be the dominating stereochemical feature also in the transformation of C(4),C(5)-disubstituted 1-[2-(3-indoly1)ethy1]-3methoxycarbonyl-1,4,5,6-tetrahydropyridines 1f and 1g to indolo[2,3a]quinolizidines 3f and 2g by the alkaline decarboalkoxylative cyclization, and seems to determinate thereby that the C(12b)H-C(2)H relationship in 3f and 2g becomes trans and cis, respectively.

The present results clearly show that the claim of ubiquitous C(12b)H-C(2)H trans product formation [= C(3)H-C(15)H trans product formation when the biogenetic numbering is used] in the alkaline decarboalkoxylative cyclization of C(4)-substituted 1-[2-(3-indoly1)ethy1]-3-methoxycarbonyl-1,4,5,6-tetrahydropyridines (and similar compounds) to <math>C(2)-substituted

indolo[2,3- $\underline{a}$ ]-quinolizidines, presented by Wenkert  $\underline{et\ al}$ . $^{4,5,7,10,11}$ , is an oversimplification that cannot be accepted.

#### EXPERIMENTAL

IR spectra were recorded with a Perkin-Elmer 700 spectrophotometer in  $CHCl_3$ , if not otherwise stated.  $^1H$  and  $^{13}C$  NMR spectra were measured with a Jeol JNM-FX 60 spectrometer working at 59.80 MHz ( $^1H$  NMR) and 15.04 MHz ( $^{13}C$  NMR). The spectra were recorded in  $CDCl_3$ . Chemical shift data are given in ppm downfield from TMS. Abbreviations s, d, t, q, m, br and def are used to designate singlet, doublet, triplet, quartet, multiplet, broad and deformed, respectively. For the  $^{13}C$  NMR data, see above. Mass spectrometry (EIMS and HRMS) was done on a Jeol DX 303/DA 5000 instrument.

Preparation of compounds <u>la</u>, <u>ld</u>, <u>le</u> and <u>lf</u> from compounds <u>5a</u>, <u>5d</u>, <u>5e</u> and <u>5f</u> Pyridinium salt <u>5a</u>, <u>5d</u>, <u>5e</u> or <u>5f</u> (3.0 mmol) in methanol (90 ml)/Et<sub>3</sub>N (0.56 ml) was hydrogenated (Pd/C, 10%, 0.33 g) for 24-48 h. Usual work-up afforded a crude product which was purified by column chromatography (alumina,  $CH_2Cl_2$ ).

Compound 1a:

Y. 63%. Mp. 137-138°C (MeOH) (lit. 1 Mp. 137-138°C).

Analytical data were identical with those described earlier. $^{f 1}$ 

Compound 1d:

Y. 61%. Viscous oil.

IR: 3320 (NH), 1670 (C=O).

<sup>1</sup>H NMR: 0.98 (3H, def,  $-CH_2-CH_2-CH_3$ ), 3.64 (3H, s,  $-CO_2CH_3$ ), 6.85 (1H, d, J=2.4 Hz, H-2'), 7.35 (1H, s, H-2), 7.16-7.44 (4H, m, H-4', 5', 6', 7'), 8.88 (1H, br s, NH).

MS: 326 (M<sup>+</sup>), 295, 283, 196 (100%), 144, 130; exact mass: 326.2000 (calculated for  $C_{20}H_{26}N_2O_2$ : 326.1990).

Compound 1e:

Y. 53%. Viscous oil.

IR: 3300 (NH), 1660 (C=O).

<sup>1</sup>H NMR: 0.91 (3H, def,  $-CH_2-\underline{CH_3}$ ), 3.66 (3H, s,  $-CO_2CH_3$ ), 6.89 (1H, d, J=2.4 Hz, H-2'), 7.37 (1H, s, H-2), 7.03-7.54 (4H, m, H-4', 5', 6', 7'), 8.64 (1H, br s, NH).

MS: 312 (M<sup>+</sup>), 281, 182 (100%), 144, 130; exact mass: 312.1851 (calc. for  $C_{19}H_{24}O_{2}N_{2}$ : 312.1838).

Compound 1f:

Y. 45%. Viscous oil.

IR: 3300 (NH), 1660 (C=O).

<sup>1</sup>H NMR: 0.90 (3H, t, J=7.0 Hz,  $-CH_2-CH_3$ ), 1.08 (3H, d, J=7.0 Hz,  $-CH_3$ ), 3.65 (3H, s,  $-CO_2CH_3$ ), 6.79 (1H, d, J=2.4 Hz, H-2'), 7.32 (1H, s, H-2), 6.98-7.57 (4H, m, H-4', 5', 6', 7'), 8.92 (1H, br s, NH).

MS: 326 (M<sup>+</sup>), 295, 196 (100%), 144, 130; exact mass: 326.2021 (calc. for  $C_{20}H_{26}N_{2}O_{2}$ : 326.1990).

### Preparation of compound 6f

 $Na_2S_2O_4$  (31.00 mmol) was added during 45 min to a stirred mixture of  $\underline{5f}$  (5.51 mmol),  $NaHCO_3$  (8.61 g), MeOH (80 ml) and  $H_2O$  (40 ml). Stirring was continued for 22 h (rt, Ar-atm). The mixture was filtered and the filtrate concentrated. The residue was extracted several times with  $CH_2Cl_2$ . The extracts were washed with  $H_2O$  and dried over  $Na_2SO_4$ . The crude product was purified by column chromatography (alumina,  $CH_2Cl_2$ ).

Y. 73%. Amorphous material.

IR: 3340 (NH), 1670 (C=O).

<sup>1</sup>H NMR: 0.96 (3H, t, J=6.0 Hz,  $-CH_2-CH_3$ ), 1.05 (3H, d, J=6.0 Hz,  $-CH_3$ ), 2.02 (2H, q, J=6.0 Hz,  $-CH_2-CH_3$ ), 3.65 (3H, s,  $-CO_2CH_3$ ), 6.87 (1H, d, J=2.4 Hz, H-2'), 7.06 and 7.18 (2H, two s, H-2 and H-6), 7.02-7.59 (4H, m, H-4', 5', 6', 7'), 8.56 (1H, br s, NH).

MS: 324 (M<sup>+</sup>), 309, 293, 144 (100%); exact mass: 324.1820 (calc. for  $C_{20}H_{24}N_{2}O_{2}$ : 324.1838).

### Preparation of compounds 1f and 1g from compound 6f

Compound  $\underline{6f}$  (1.5 mmol) in MeOH (90 ml)/Et<sub>3</sub>N (0.3 ml) was hydrogenated (Pd/C, 10%, 175 mg) for 8 h. Usual work-up afforded a 70:30 mixture of compounds  $\underline{1f}$  and  $\underline{1g}$  (Y. 58%). TLC was used to get pure samples for spectroscopical analysis. Otherwise the mixture was used as such in the next step ( $\underline{vide}$   $\underline{infra}$ ).

#### Compound 1f:

Analytical data were identical with those described above for compound  $\underline{1f}$ . Compound  $\underline{1g}$ :

IR: 3310 (NH), 1660 (C=O).

<sup>1</sup>H NMR: 0.89 (3H, t, J=7.0 Hz,  $-CH_2-CH_3$ ), 1.03 (3H, d, J=7.0 Hz,  $-CH_3$ ), 3.65 (3H, s,  $-CO_2CH_3$ ), 6.94 (1H, d, J=2.4 Hz, H-2'), 7.30 (1H, s, H-2), 7.04-7.64 (4H, m, H-4', 5', 6', 7'), 8.31 (1H, br s, NH).

MS: 326 (M<sup>+</sup>), 295, 196 (100%), 144, 130; exact mass: 326.1987 (calc. for  $C_{20}H_{26}N_2O_2$ : 326.1990).

# Preparation of compounds 2a, 3a, 2d and 3d by alkaline decarboalkoxylative cyclization

Compound  $\underline{1a}$  or  $\underline{1d}$  (1.50 mmol) was dissolved in MeOH (35 ml). KOH (5.50 g) and H<sub>2</sub>O (23 ml) were added. The mixture was refluxed for 48 h (Ar-atm). MeOH was evaporated and H<sub>2</sub>O added. The solution was extracted several times with CH<sub>2</sub>Cl<sub>2</sub> and dried over Na<sub>2</sub>SO<sub>4</sub>.

A mixture of two isomers 2a and 3a (~ 90:10) or 2d and 3d (~ 80:20) was obtained. The crude product was purified by TLC.

### Compound 2a:

Y. 30%. Mp. 165-166°C (MeOH) (lit. Mp. 165-166°C).

Analytical data were identical with those described earlier. 1

### Compound 3a:

Y. 3%. Mp. 154-155°C ( $C_6H_6$ , petroleum ether addition) (lit.  $^{21}$  154-155°C). Analytical data were identical with those described earlier.  $^{21}$  Compound 2d:

Y. 27%. Mp. 80-81°C (EtOH).

IR: 3430 (NH), 2830 and 2770 (Bohlmann bands).

<sup>1</sup>H NMR: 0.91 (3H, t, J=6.0 Hz, -CH<sub>3</sub>), 6.97-7.52 (4H, m, H-8, 9, 10, 11), 8.17 (1H, br s, NH).

MS: 268 (M<sup>+</sup>), 267 (100%), 225, 197, 170, 169; exact mass: 268.1913 (calc. for  $C_{18}H_{24}N_2$ : 268.1939).

### Compound 3d:

Y. 6%. Amorphous material.

IR: 3440 (NH).

 $^{1}$ H NMR: 0.93 (3H, def, -CH<sub>3</sub>), 3.92 (1H, m, H-12b), 7.01-7.54 (4H, m, H-8, 9, 10, 11), 8.08 (1H, br s, NH).

MS: 268 (M<sup>+</sup>), 267 (100%), 225, 197, 170, 169; exact mass: 268.1919 (calc. for  $C_{18}H_{24}N_2$ : 268.1939).

# Preparation of compounds $\underline{3e}$ and $\underline{2e}$ by alkaline decarboalkoxylative cyclization

Compounds  $\underline{3e}$  and  $\underline{2e}$  were prepared from compound  $\underline{1e}$  using the same procedure (<u>vide supra</u>) as described for the preparation of compounds  $\underline{2a}$ ,  $\underline{3a}$ ,  $\underline{2d}$  and  $\underline{3d}$  (reaction time 64 h).

### Compound 3e:

Y. 90%. Mp. 159-161°C (EtOH) (lit. Mp. 159-161°C $^{31}$ , 160-161°C $^{34}$ , 157°C $^{35}$ ). Analytical data were identical with those described earlier $^{31}$ ,  $^{34}$ ,  $^{35}$ . Compound 2e:

Y. 2%. Amorphous material.

Analytical data were identical with those described earlier. 22

# Preparation of compounds 3f and 2f by alkaline decarboalkoxylative cyclization

Compounds  $\underline{3f}$  and  $\underline{2f}$  were prepared from  $\underline{1f}$  using the same procedure (<u>vide supra</u>) as described for the preparation of compounds  $\underline{2a}$ ,  $\underline{3a}$ ,  $\underline{2d}$  and  $\underline{3d}$  (reaction time 192 h).

Compound 3f:

Y. 59%. Amorphous material.

IR: 3440 (NH), 2850 and 2780 (Bohlmann bands).

<sup>1</sup>H NMR: 0.91 (3H, def,  $-CH_2-CH_3$ ), 0.95 (3H, d, J=7.0 Hz,  $-CH_3$ ), 3.52 (1H, m, H-12b), 6.99-7.44 (4H, m, H-8, 9, 10, 11), 7.98 (1H, br s, NH).

MS: 268 (M<sup>+</sup>), 267 (100%), 170, 169; exact mass: 268.1908 (calc. for  $C_{18}H_{24}N_2$ : 268.1939).

Compound 2f:

Y. 1-2%. Amorphous material.

IR: 3440 (NH), 2830 and 2780 (Bohlmann bands).

<sup>1</sup>H NMR: 0.89 (3H, def,  $-CH_2-CH_3$ ), 0.94 (3H, d, J=7.0 Hz,  $-CH_3$ ), 6.97-7.52 (4H, m, H-8, 9, 10, 11), 7.72 (1H, br s, NH).

MS: 268 (M<sup>+</sup>), 267 (100%), 170, 169; exact mass: 268.1927 (calc. for  $C_{18}H_{24}N_2$ : 268.1939).

# Preparation of compounds 3f, 2f and 2g by alkaline decarboalkoxylative cyclization

Compounds  $\underline{3f}$ ,  $\underline{2f}$  and  $\underline{2g}$  were prepared from the 70:30 mixture of  $\underline{1f}$  and  $\underline{1g}$  using the same procedure (vide supra) as described for the preparation of compounds  $\underline{2a}$ ,  $\underline{3a}$ ,  $\underline{2d}$  and  $\underline{3d}$  (reaction time 192 h).

Compound 3f:

Y. 41%. Amorphous material.

Analytical data were identical with those described above for compound  $\underline{3f}$ . Compound  $\underline{2f}$ :

Y. 1%. Amorphous material.

Analytical data were identical with those described above for compound  $\underline{2f}$ . Compound  $\underline{2g}$ :

Y. 18%. Amorphous material.

IR: 3430 (NH), 2830 and 2780 (Bohlmann bands).

<sup>1</sup>H NMR: 0.97 (3H, def,  $-CH_2-CH_3$ ), 0.97 (3H, def,  $-CH_3$ ), 6.98-7.53 (4H, m, H-8, 9, 10, 11), 8.08 (1H, br s, NH).

MS: 268 (M<sup>+</sup>), 267 (100%), 170, 169; exact mass: 268.1927 (calc. for  $C_{18}H_{24}N_2$ : 268.1939).

### Preparation of compounds 9a, 9d, 9e and 9f

Compounds  $\underline{9a}$ ,  $\underline{9d}$ ,  $\underline{9e}$  and  $\underline{9f}$  were prepared by NaBH<sub>4</sub> reduction and cyanide trapping from the corresponding pyridinium salts  $\underline{7a}$ ,  $\underline{7d}$ ,  $\underline{7e}$  and  $\underline{7f}$ , respectively, using the procedure described in Ref. 21.

### Compound 9a:

Y. 93%. Amorphous material.

Analytical data were identical with those described earlier. 21 Compound 9d:

Y. 90%. Amorphous material.

IR: 3440 (NH), 2290 (CN).

<sup>1</sup>H NMR: 0.87 (3H, t, J=7.0 Hz, -CH<sub>3</sub>), 3.89 (1H, m, H-2), 5.39 (1H, br s, H-5), 6.88 (1H, d, J=2.4 Hz, H-2'), 7.05-7.63 (4H, m, H-4', 5', 6', 7'), 8.05 (1H, br s, NH).

MS: 293 (M<sup>+</sup>), 266, 163, 144, 138 (100%), 136, 130; exact mass: 293.1866 (calc. for  $C_{19}H_{23}N_3$ : 293.1892).

Compound 9e:

Y. 90%. Viscous oil.

Analytical data were identical with those described earlier. 31

Compound 9f:

Y. 62%. Viscous oil.

IR: 3440 (NH), 2260 (CN).

<sup>1</sup>H NMR: 0.96 (3H, t, J=7.0 Hz,  $-CH_2-CH_3$ ), 1.61 (3H, s,  $-CH_3$ ), 1.88 (2H, q, J=7.0 Hz,  $-CH_2-CH_3$ ), 3.84 (1H, m, H-2), 6.83 (1H, d, J=2.4 Hz, H-2'), 6.99-7.64 (4H, m, H-4', 5', 6', 7'), 8.09 (1H, br s, NH).

MS: 293 (M<sup>+</sup>), 266, 251, 163, 144 (100%), 138, 130; exact mass: 293.1895 (calc. for  $C_{19}H_{23}N_3$ : 293.1892).

## Preparation of compounds 10a, 10d, 10e and 10f

Compounds  $\underline{10a}$ ,  $\underline{10d}$ ,  $\underline{10e}$  and  $\underline{10f}$  were prepared by AcOH treatment from compounds  $\underline{9a}$ ,  $\underline{9d}$ ,  $\underline{9e}$  and  $\underline{9f}$ , respectively, using the procedure described in Ref. 21.

Compound 10a:

Y. 54%. Amorphous material.

Analytical data were identical with those described earlier. <sup>21</sup> Compound 10d:

Y. 47%. Mp. 70-71°C (EtOH).

IR: 3430 (NH).

 $^{1}$ H NMR: 0.86 (3H, t, J=6.0 Hz, -CH<sub>3</sub>), 5.43 (1H, br s, H-3), 7.08-7.55 (4H, m, H-8, 9, 10, 11), 7.93 (1H, br s, NH).

MS: 266 (M<sup>+</sup>), 265, 170 (100%), 169; exact mass: 266.1779 (calc. for  $C_{18}H_{22}N_2$ : 266.1783).

Compound 10e:

Y. 44%. Mp. 146-148°C (EtOH) (lit. 143-145°C $^{37}$ ; 147-148°C $^{38}$ ; 146-148°C $^{31}$ ). Analytical data were identical with those described earlier.  $^{31}$  Compound 10f:

Y. 45%. Mp. 178-179°C (MeOH).

IR: 3440 (NH).

<sup>1</sup>H NMR: 0.97 (3H, t, J=7.0 Hz,  $-CH_2-CH_3$ ), 1.62 (3H, s,  $-CH_3$ ), 2.02 (2H, q, J=7.0 Hz,  $-CH_2-CH_3$ ), 7.02-7.54 (4H, m, H-8, 9, 10, 11), 7.72 (1H, br s, NH).

MS: 266 (M<sup>+</sup>), 265, 170 (100%), 169; exact mass: 266.1759 (calc. for  $C_{18}H_{22}N_2$ : 266.1783).

# Preparation of compounds $\underline{2a}$ , $\underline{2d}$ , $\underline{2e}$ and $\underline{2f}$ from compounds $\underline{10a}$ , $\underline{10d}$ , $\underline{10e}$ and 10f

Catalytic hydrogenation (PtO<sub>2</sub>) of compounds  $\underline{10a}$ ,  $\underline{10d}$ ,  $\underline{10e}$  and  $\underline{10f}$  afforded compounds  $\underline{2a}$ ,  $\underline{2d}$ ,  $\underline{2e}$  and  $\underline{2f}$ , respectively.

Compound 2a:

Y. 72%. Mp. 165-166°C (EtOH) (lit. 1 Mp. 165-166°C).

Analytical data were identical with those of compound 2a described above. Compound 2d:

Y. 70%. Mp. 80-81°C (EtOH).

Analytical data were identical with those of compound 2d described above. Compound 2e:

Y. 60%. Amorphous material.

Analytical data were identical with those described earlier.  $^{22}$  Compound 2f:

Y. 95%. Amorphous material.

Analytical data were identical with those of compound 2f described above.

# Preparation of compounds 11a, 11d, 11e and 11f

Compounds <u>11a</u>, <u>11d</u>, <u>11e</u> and <u>11f</u> were prepared by di-t-butyl dicarbonate [(BOC)<sub>2</sub>O] treatment from compounds <u>10a</u>, <u>10d</u>, <u>10e</u> and <u>10f</u>, respectively, using the procedure described in Ref. 21.

Compound 11a:

Y. 95%. Viscous oil.

Analytical data were identical with those described earlier.  $^{21}$  Compound 11d:

Y. 90%. Viscous oil.

IR: 1730 (C=O).

<sup>1</sup>H NMR: 0.90 (3H, t, J=6.0 Hz,  $-\text{CH}_3$ ), 1.65 (9H, s,  $-\text{C(CH}_3)_3$ ), 4.08 (1H, br d, H-12b), 5.48 (1H, br s, H-3), 7.14-7.51 (3H, m, H-8, 9, 10), 8.08 (1H, m, H-11).

MS: 366 (M<sup>+</sup>), 310, 309, 214 (100%), 170, 169; exact mass: 366.2319 (calc. for  $C_{23}H_{30}N_{2}O_{2}$ : 366.2307).

Compound 11e:

Y. 90%. Viscous oil.

Analytical data were identical with those described earlier. 31 Compound 11f:

Y. 90%. Viscous oil.

IR: 1720 (C=O).

<sup>1</sup>H NMR: 1.00 (3H, t, J=7.0 Hz,  $-CH_2-CH_3$ ), 1.63 (12 H, s,  $-CH_3$  and  $-C(CH_3)_3$ ), 2.05 (2H, q, J=7.0 Hz,  $-CH_2-CH_3$ ), 4.03 (1H, br d, H-12b), 7.12-7.39 (3H, m, H-8, 9, 10), 8.08 (1H, m, H-11).

MS: 366 (M<sup>+</sup>), 310, 309, 214 (100%), 170, 169; exact mass: 366.2310 (calc. for  $C_{23}H_{30}N_2O_2$ : 366.2307).

### Preparation of compounds 12a, 12d, 12e and 12f

Catalytic hydrogenation (PtO<sub>2</sub>) of compounds  $\underline{11a}$ ,  $\underline{11d}$ ,  $\underline{11e}$  and  $\underline{11f}$  afforded compounds  $\underline{12a}$ ,  $\underline{12d}$ ,  $\underline{12e}$  and  $\underline{12f}$ , respectively.

Compound 12a:

Y. 85%. Amorphous material.

Analytical data were identical with those described earlier. 21

Compound 12d:

Y. 95%. Viscous oil.

IR: 1730 (C=O).

<sup>1</sup>H NMR: 0.91 (3H, def, -CH<sub>3</sub>), 1.67 (9H, s, -C(CH<sub>3</sub>)<sub>3</sub>), 4.47 (1H, m, H-12b), 7.12-7.34 (3H, m, H-8, 9, 10), 7.95 (1H, m, H-11).

MS: 368 (M<sup>+</sup>), 312, 311 (100%), 267, 215; exact mass: 368.2472 (calc. for  $C_{23}H_{32}N_2O_2$ : 368.2464).

Compound 12e:

Y. 75%. Viscous oil.

Analytical data were identical with those described earlier.  $^{31}$ 

Compound 12f:

Y. 73%. Viscous oil.

IR: 1730 (C=O).

<sup>1</sup>H NMR: 0.91 (3H, t, J=7.0 Hz,  $-CH_2-\underline{CH_3}$ ), 1.06 (3H, d, J=7.0 Hz,  $-CH_3$ ), 1.67 (9H, s,  $-C(CH_3)_3$ ), 4.28 (1H, br d, H-12b), 7.01-7.48 (3H, m, H-8, 9, 10), 7.94 (1H, m, H-11).

MS:  $368 \, (M^+)$ , 312,  $311 \, (100\%)$ , 267, 215; exact mass:  $368.2409 \, (calc. for$  $C_{23}H_{32}N_{2}O_{2}$ : 368.2464).

# Preparation of compounds 3a, 3d, 3e and 3f from compounds 12a, 12d, 12e and 12f

Compounds 3a, 3d, 3e and 3f were prepared by HCOOH treatment from compounds 12a, 12d, 12e and 12f, respectively, using the procedure described in Ref. 21.

## Compound 3a:

Y. 95%. Mp. 154-155°C ( $C_6H_6$ , petroleum ether addition) (lit.<sup>21</sup> Mp. 154-

Analytical data were identical with those described above for compound 3a. Compound 3d:

Y. 95%. Amorphous material.

Analytical data were identical with those described above for compound 3d. Compound 3e:

Y. 80%. Mp. 159-161°C (EtOH) (lit. Mp. 159-161°C<sup>31</sup>, 160-161°C<sup>34</sup>, 157°C<sup>35</sup>). Analytical data were identical with those described above for compound 3e. Compound 3f:

Y. 90%. Amorphous material.

Analytical data were identical with those described above for compound 3f.

#### REFERENCES AND NOTES

- Lounasmaa, M.; Jokela, R. Tetrahedron 1978, 34, 1841. 1.
- Lounasmaa, M.; Johansson, C.-J.; Svensson, J. Acta Chem. Scand. 2. 1976, <u>B30</u>, 251.
- Lounasmaa, M.; Hämeilä, M. Tetrahedron 1978, 34, 437. 3.
- 4. Wenkert, E.; Dave, K.G.; Haglid, F. J. Am. Chem. Soc. 1965, 87, 5461.
- 5. Wenkert, E.; Dave, K.G.; Lewis, R.G.; Sprague, P.W. J. Am. Chem. <u>Soc.</u> 1967, <u>89</u>, 6741.
- LeMen, J.; Taylor, W. Experientia 1965, 21, 508. 6.
- Wenkert, E.; Sprague, P.W.; Webb, R.L. J. Org. Chem. 1973, 38, 4305. 7.
- 8.
- Lounasmaa, M.; Jokela, R. <u>Tetrahedron</u> 1989, 45, 7449. Lounasmaa, M.; Jokela, R. The results were first presented as part of a series of lectures at the Technical University of Helsinki 9. (Autumn 1989).
- 10. Wenkert, E.; Han, A.-L.; Michelotti, E.L. Croatica Chem. Acta 1985, <u>58</u>, 737.
- 11. Wenkert, E.; Moeller, P.D.R.; Shi, Y.-J. J. Org. Chem. 1988, 53,
- 12.
- Lounasmaa, M.; Johansson, C.-J. <u>Tetrahedron</u> 1977, <u>33</u>, 113. Jokela, R.; <u>Tamminen</u>, T.; <u>Lounasmaa</u>, <u>M. <u>Heterocycles</u> 1985, <u>33</u>, 1707.</u> 13.
- 14. Hoshino, T.; Shimodaira, K. Liebigs Ann. Chem. 1935, 520, 19.
- Lounasmaa, M.; Juutinen, P.; Kairisalo, P. Tetrahedron 1978, 34, 15. 2529.
- 16. Lounasmaa, M.; Merikallio, H; Puhakka, M. Tetrahedron 1978, 34,2995.
- 17. Lounasmaa, M.; Jokela, R. Tetrahedron Lett. 1978, 3609.

- 18. Frostell, E.; Jokela, R.; Lounasmaa, M. Acta Chem. Scand. 1981, <u>B35</u>, 671.
- 19. Jokela, R.; Lounasmaa, M. Tetrahedron 1982, 38, 1015.
- The exclusive formation of 2-methyl-3-ethylindolo[2,3-a]quinolizidine 2g [C(12b)H-C(2)H cis relationship = C(3)H-C(15)H cis relationship when the biogenetic numbering of indole alkaloids 20. is used] using 1,4,5,6-tetrahydropyridine 1g [C(4)H-C(5)H trans relationship = C(15)H-C(20)H <u>trans</u> relationship when the biogenetic numbering of indole alkaloids is applied in <u>sensu</u> <u>lato</u> to the 1-[2-(3-indoly1)ethy1]-3-methoxycarbony1-1,4,5,6-tetrahydropyridines] is of special interest when compared with the statement (Ref. 4, Note 22): "The uniform formation of 3,15-trans compounds in the cyclization of 2,3-seco-3-dehydro substances is consistent with a similar observation in the case of a 15,20-trans compound". See also, Ref. 10, Equation b.
- 21. Lounasmaa, M.; Jokela, R. Tetrahedron 1989, 45, 3975.
- Lounasmaa, M.; Jokela, R.; Tirkkonen, B.; Tamminen, T. Tetrahedron 22. 1989, <u>45</u>, 7615.
- 23. Lounasmaa, M.; Jokela, R. Tetrahedron (in press).
- 24. Aldrich, Compound 23,961-5.
- 25. K&K, Compound 217169.
- Aldrich, Compound 14,239-5. 26.
- Fluka, Compound 535642. 27. Small amounts of compound 3e were also formed (cf. Ref. 22). 28.
- case of compounds 12e and 12f, the small amounts of the C(12b) epimers  $\underline{i}$  (cf. Ref. 31, compound 11) and 11 were 29. separated.

After reconsideration of the  $^{13}\mathrm{C}$  NMR spectrum of compound 11 in Ref. 31 (= compound  $\underline{\mathbf{i}}$ ) we have interchanged the C(12b) and C(4) signals. A similar interchange for compound 14 in Ref. 22 is obvious.

- It should be noted that Scheme 8 is drawn in such a way that optical 30. antipodes of compounds 10a,d,e,f are involved in the formation of compounds 2a,d,e,f and 12a,d,e,f.
- Tamminen, T.; Jokela, R.; Tirkkonen, B.; Lounasmaa, M. <u>Tetrahedron</u> 1989, 45, 2683. 31.
- Lounasmaa, M.; Jokela, R.; Tamminen, T. Heterocycles 1985, 23, 1367. 32.
- See also, Ref. 31, Note 15, and Ref. 36, Note 15.

  Lounasmaa, M. in "Studies in Natural Products Chemistry", ed. Attaur-Rahman, Vol. 1, Stereoselective Synthesis (Part A), Elsevier, Amsterdam, 1988, pp. 89-122.

  Yamanaka, E.; Narushima, M.; Inukai, K.; Sakai, S.-I. Chem. Pharm. 33.
- 34. <u>Bull.</u> 1986, <u>34</u>, 77.
- Massiot, G.; Oliveira, F.S.; Levy, J. Bull. Soc. Chim. France II 35. 1982, 185.
- Jokela, R.; Karvinen, E.; Tolvanen, A.; Lounasmaa, M. Tetrahedron 36. 1988, 44, 2367.
- Wenkert, E.; Massy-Westropp, R.A.; Lewis, R.G. J. Am. Chem. Soc. 37. 1962, 84, 3732.
- Fry, E.M.; Beisler, J.A. <u>J. Org. Chem.</u> 1970, <u>35</u>, 2809. 38.